Video

Dr. Marmarelis on the Efficacy of Lazertinib/Amivantamab Plus Chemotherapy in EGFR-Mutated NSCLC

Melina Elpi Marmarelis, MD, discusses the efficacy of lazertinib and amivantamab-vmjw plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer.

Melina Elpi Marmarelis, MD, hematology, medical oncology, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the efficacy of lazertinib (Leclaza) and amivantamab-vmjw (Rybrevant) plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

The phase 1 CHRYSALIS-2 trial (NCT04077463) is examining the use of lazertinib as a single agent and in combination with amivantamab, with or without chemotherapy, for patients with advanced or metastatic EGFR mutations.

Findings presented at the 2022 World Conference on Lung Cancer showed that the combination of lazertinib and amivantamab plus carboplatin and pemetrexed elicited an overall response rate (ORR) of 50% in the overall population (n = 20), plus an ORR of 50% in 10 patients that had prior brain metastases, Marmarelis says. Compared with observed ORRs for chemotherapy alone or the combination of amivantamab and lazertinib without chemotherapy in this patient population, these responses were impressive, Marmarelis explains.

At the time of data cutoff with a median follow-up of about 7 months, 15 of 20 patients remained on treatment, Marmarelis continues. Though investigators are currently unable to estimate the median duration of response, data have pointed to patients are having durable responses, Marmarelis concludes.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD